Group 1: Shareholder Information - The major shareholder is Mr. Du Jiangtao, holding 39.03% of the company's shares. He also holds 31.95% of another listed company, Junzheng Group (stock code: 601216) [3]. Group 2: Blood Product Business Development - The company has made continuous investments in product research and development, as well as plasma station expansion, achieving a total of 7 product approvals [3]. - Currently, there are 15 operational plasma stations, with 7 located in Guangdong and 6 in Hebei [3]. Group 3: Production and Quality Control - The Yunnan blood product project is undergoing a qualification transfer process, which requires government approval and cannot be accurately estimated for completion [4]. - The company’s blood product gross margin is currently low due to high procurement costs from 2021 and promotional policies for new customers [4]. Group 4: Inventory and Research - The majority of the company's inventory consists of raw plasma and plasma components [4]. - Ongoing research projects mainly focus on microfluidic technology platforms, covering areas such as respiratory, intestinal, and reproductive health [4]. Group 5: Sales and Marketing Strategy - The company has established a unified marketing team in the medical field to manage IVD and biopharmaceutical business resources, aiming to enhance the efficiency of the marketing team [5].
博晖创新(300318) - 2023年6月26日投资者关系活动记录表